Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Selection, identification, and characterization of SARS-CoV-2 monoclonal antibody resistant mutants.

Journal of virological methods - 1 Apr 2021

Oladunni Fatai S, Park Jun-Gyu, Chiem Kevin, Ye Chengjin, Pipenbrink Michael, Walter Mark R, Kobie James, Martinez-Sobrido Luis

Abstract excerpt

The use of monoclonal neutralizing antibodies (mNAbs) is being actively pursued as a viable intervention for the treatment of Severe Acute Respiratory Syndrome CoV-2 (SARS-CoV-2) infection and associated coronavirus disease 2019 (COVID-19). While highly potent mNAbs have great therapeutic potential, the ability of the virus to mutate and escape recognition and neutralization of mNAbs represents a potential...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Neutralizing
Share to Antigenic Variation

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Chlorocebus aethiops

Share to COVID-19

Share to COVID-19 Drug Treatment

Share to SARS-CoV-2

Share to Spike Glycoprotein, Coronavirus

Share to Vero Cells

Source

Open in PubMed Open full text

Identifiers

PMID: 33513380
DOI: 10.1016/j.jviromet.2021.114084
PMCID: PMC7837211

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Selection, identification, and characterization of SARS-CoV-2 monoclonal antibody resistant mutants.PMID 33513380Read ↗

The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies.Semantic proximity Read ↗

Emergence of SARS-CoV-2 resistance mutations in a patient who received anti-SARS-COV2 spike protein monoclonal antibodies: a case report.Semantic proximity Read ↗

Identification of antibody-resistant SARS-CoV-2 mutants via N4-Hydroxycytidine mutagenesis.Semantic proximity Read ↗

Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognitionSemantic proximity Read ↗

Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody RecognitionSemantic proximity Read ↗

Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization.Semantic proximity Read ↗

Long-term passaging of replication competent pseudo-typed SARS-CoV-2 reveals the antiviral breadth of monoclonal and bispecific antibody cocktailsSemantic proximity Read ↗

In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strainsSemantic proximity Read ↗

Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016Semantic proximity Read ↗

Emerging mutations in the SARS-CoV-2 variants and their role in antibody escape to small molecule-based therapeutic resistance.Semantic proximity Read ↗

Isolation and characterization of neutralizing monoclonal antibodies from a large panel of murine antibodies against RBD of the SARS-CoV-2 Spike proteinSemantic proximity Read ↗

Impact of mAb-induced A475V substitution on viral fitness and antibody neutralization of SARS-CoV-2 omicron variants in the presence of monoclonal antibodies and human convalescent seraSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.